ABIOMED, Inc. (ABMD) Shares Bought by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC raised its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 8.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,930 shares of the medical equipment provider’s stock after buying an additional 157 shares during the period. Flagship Harbor Advisors LLC’s holdings in ABIOMED were worth $551,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABMD. JPMorgan Chase & Co. raised its stake in shares of ABIOMED by 7.2% in the third quarter. JPMorgan Chase & Co. now owns 364,775 shares of the medical equipment provider’s stock valued at $164,057,000 after acquiring an additional 24,531 shares in the last quarter. Martingale Asset Management L P acquired a new stake in shares of ABIOMED in the third quarter valued at $2,183,000. Dimensional Fund Advisors LP raised its stake in shares of ABIOMED by 1.2% in the third quarter. Dimensional Fund Advisors LP now owns 144,681 shares of the medical equipment provider’s stock valued at $65,065,000 after acquiring an additional 1,764 shares in the last quarter. Standard Life Aberdeen plc raised its stake in shares of ABIOMED by 1.7% in the third quarter. Standard Life Aberdeen plc now owns 124,192 shares of the medical equipment provider’s stock valued at $55,864,000 after acquiring an additional 2,095 shares in the last quarter. Finally, Pacer Advisors Inc. raised its stake in shares of ABIOMED by 17.9% in the third quarter. Pacer Advisors Inc. now owns 2,328 shares of the medical equipment provider’s stock valued at $1,047,000 after acquiring an additional 354 shares in the last quarter. Institutional investors and hedge funds own 87.94% of the company’s stock.

In other ABIOMED news, Director Martin P. Sutter sold 19,943 shares of the firm’s stock in a transaction on Monday, February 4th. The stock was sold at an average price of $350.28, for a total value of $6,985,634.04. Following the sale, the director now directly owns 212,943 shares in the company, valued at $74,589,674.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Martin P. Sutter sold 5,985 shares of the firm’s stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $349.49, for a total value of $2,091,697.65. Following the completion of the sale, the director now owns 212,943 shares in the company, valued at $74,421,449.07. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,928 shares of company stock worth $26,515,812. 3.50% of the stock is owned by insiders.

ABIOMED stock opened at $265.95 on Wednesday. ABIOMED, Inc. has a 1-year low of $264.54 and a 1-year high of $459.75. The firm has a market capitalization of $12.28 billion, a price-to-earnings ratio of 81.04, a price-to-earnings-growth ratio of 1.99 and a beta of 0.33.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.03. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. The company had revenue of $200.56 million for the quarter, compared to analysts’ expectations of $200.60 million. Equities research analysts predict that ABIOMED, Inc. will post 3.59 EPS for the current year.

Several analysts have recently issued reports on the company. Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. BidaskClub cut ABIOMED from a “sell” rating to a “strong sell” rating in a research note on Saturday. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. ABIOMED has an average rating of “Hold” and an average target price of $422.40.

ILLEGAL ACTIVITY NOTICE: “ABIOMED, Inc. (ABMD) Shares Bought by Flagship Harbor Advisors LLC” was reported by Modern Readers and is the sole property of of Modern Readers. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.modernreaders.com/news/2019/04/17/abiomed-inc-abmd-shares-bought-by-flagship-harbor-advisors-llc.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.